Department of Chemistry, York University, 4700 Keele Street Toronto, Ontario, Canada M3J 1P3.
Anal Chem. 2020 Jun 2;92(11):7373-7381. doi: 10.1021/acs.analchem.0c00711. Epub 2020 May 19.
The detection of biomarkers is critical for enabling early disease diagnosis, monitoring the progression, and tracking the effectiveness of therapeutic intervention. Plasmonic sensors exhibit a broad range of analytical capabilities, from the rapid generation of colorimetric readouts to single-molecule sensitivity in ultralow sample volumes, which have led to their increased exploration in bioanalysis and point-of-care applications. This perspective presents selected accounts of recent developments on the different types of plasmonic sensing platforms, the pervasive challenges, and outlook on the pathway to translation. We highlight the sensing of upcoming biomarkers, including microRNA, circulating tumor cells, exosomes, and cell-free DNA, and discuss the opportunity of utilizing plasmonic nanomaterials and tools for biomarker detection beyond biofluids, such as in tissues, organs, and disease sites. The integration of plasmonic biosensors with established and upcoming technologies of instrumentation, sample pretreatment, and data analysis will help realize their translation to clinical settings for improving healthcare and enhancing the quality of life.
生物标志物的检测对于实现疾病的早期诊断、监测疾病进展和跟踪治疗干预效果至关重要。等离子体传感器具有广泛的分析能力，从快速产生比色读出到在超低样品体积中单分子灵敏度，这导致它们在生物分析和即时检测应用中的应用日益增加。本观点介绍了等离子体传感平台的不同类型的最新进展、普遍存在的挑战以及向转化途径的展望。我们强调了对即将出现的生物标志物的检测，包括 microRNA、循环肿瘤细胞、外泌体和无细胞 DNA，并讨论了利用等离子体纳米材料和工具进行生物标志物检测的机会，超越了生物流体，如在组织、器官和疾病部位。等离子体生物传感器与现有的和即将出现的仪器仪表技术、样品预处理和数据分析的集成将有助于实现它们向临床环境的转化，以改善医疗保健和提高生活质量。
